JBIO

Jade Biosciences
JBIO

16.04 USD
+0.79
5.18%
At close Updated Dec 16, 4:00 PM EST
Pre-market
After hours
16.35
+0.31
1.93%
1 day
5.18%
5 days
19.7%
1 month
27.4%
3 months
124.65%
6 months
129.47%
Year to date
-82.96%
1 year
-82.1%
5 years
-97.99%
10 years
-97.99%
 

About: Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Healthcare Biotechnology
0
Funds holding %
of 7,516 funds
Explore Fund Trends
0
Analysts bullish %
of 3 analysts
See Analyst Outlook
0
Positive news %
of 4 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™